Please assess the completion status of the following clinical trial:

Trial Title: Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Criteria:~* WBC \>= 3,000/mm\^3~* LVEF normal~* Histologically or cytologically confirmed hepatocellular carcinoma; Advanced disease, unresectable disease, no Childs C criteria~* Measurable disease, defined as \>= 1 unidimensionally measurable lesion \>= 20 mm by conventional techniques or \>= 10 mm by spiral CT scan~* Not a candidate for percutaneous ethanol injection or radiofrequency ablation (RFA)~* Prior transarterial chemoembolization, ethanol, and RFA allowed if new lesions are present in the liver and there are no other sites of disease~* No pleural effusion or ascites requiring paracentesis within the past 4 weeks~* No known brain metastases~* ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%~* Life expectancy \> 3 months~* Absolute neutrophil count \>= 1,500/mm\^3~* Platelet count \>= 75,000/mm\^3~* Bilirubin =\< 2 times upper limit of normal (ULN)~* AST and ALT =\<2.5 times ULN (5 times ULN if liver involvement by tumor)~* Creatinine =\< 2 times ULN~* PT =\< 1.5 times ULN (no anticoagulation)~* Albumin \>= 2.5 mg/dL~* No history of allergic reactions attributed to compounds of similar chemical or biological composition to dasatinib~* No evidence of encephalopathy~* No condition that would preclude ability to swallow and retain dasatinib tablets, including any of the following:~  * Gastrointestinal tract disease resulting in an inability to take oral medication;~ * Requirement for IV alimentation;~ * Prior surgical procedures affecting absorption:~ * Active peptic ulcer disease~* No clinically significant ECG abnormalities~* No clinically significant cardiovascular disease, including any of the following:~  * Myocardial infarction or ventricular tachyarrhythmia within the past 6 months;~ * Prolonged QTc \>= 480 msec (Fridericia correction);~ * Major conduction abnormality (unless cardiac pacemaker is present)~* No other uncontrolled illness, including, but not limited to, any of the following:~  * Ongoing or active infection;~ * History of significant bleeding disorder, including congenital (von Willebrand's disease) or acquired disorders (antifactor VIII antibodies);~ * Psychiatric illness or social situation that would preclude study compliance~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Recovered from all prior therapy~* One prior systemic chemotherapy regimen allowed~* Prior cryosurgery allowed~* More than 4 weeks since prior transarterial chemoembolization~* More than 4 weeks since prior radiotherapy~* Prior or concurrent localized palliative radiotherapy (i.e., bony metastasis) allowed provided it was administered for =\< 3 days~* At least 7 days since prior and no concurrent antithrombotic and/or antiplatelet agents (e.g., warfarin, heparin, low molecular weight heparin, acetylsalicylic acid, and/or ibuprofen)~* At least 7 days since prior and no concurrent agents with proarrhythmic potential~* At least 7 days since prior and no concurrent medications or substances that are potent inhibitors or inducers of CYP3A4~* No concurrent combination antiretroviral therapy for HIV-positive patients~* No concurrent embolization or chemoembolization~* No concurrent systemic antacids (H2 receptor antagonists or proton pump inhibitors)~* Locally active antacids allowed provided they are held for 2 hours before and 2 hours after dasatinib dose~* No other concurrent investigational agents~* No other concurrent anticancer agents or therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral Dasatinib (Type: EXPERIMENTAL): Patients receive oral dasatinib at 70 mg twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).